TGF-β and Hepatocellular Carcinoma: When A Friend Becomes An Enemy

Marco Arrese, Alejandra Hernandez, Luis Astete, Lisbell Estrada, Claudio Cabello-Verrugio, Daniel Cabrera

Resultado de la investigación: Article

1 Cita (Scopus)

Resumen

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy. A key molecular player capable of modulating cell growth and fibrosis is the Transforming Growth Factor-beta (TGF-β). Interestingly, TGF-β seems to act like a switch, since it has dual and opposite roles during early and late phases of cancer development. Therefore to develop therapies that target TGF-β signaling pathway for HCC treatment is important to understand the underlying pathogenetic mechanisms at play with special emphasis in the crosstalk between TGF-β and other signaling pathways. In recent years, a plethora of TGR-β have been developed and some of them are under clinical investigations for testing in patients with advanced HCC. In this review, we summarize recent knowledge about the role of TGF-β signaling pathway in HCC progression.

Idioma originalEnglish
Páginas (desde-hasta)1172-1179
Número de páginas8
PublicaciónCurrent protein & peptide science
Volumen19
N.º12
DOI
EstadoPublished - 1 ene 2018

Huella dactilar

Transforming Growth Factor beta
Hepatocellular Carcinoma
Fibrosis
Cell growth
Neoplasms
Crosstalk
Liver
Switches
Cause of Death
Tissue
Therapeutics
Pharmacology
Testing
Growth

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Citar esto

Arrese, Marco ; Hernandez, Alejandra ; Astete, Luis ; Estrada, Lisbell ; Cabello-Verrugio, Claudio ; Cabrera, Daniel. / TGF-β and Hepatocellular Carcinoma : When A Friend Becomes An Enemy. En: Current protein & peptide science. 2018 ; Vol. 19, N.º 12. pp. 1172-1179.
@article{e2af7dca9de14645a8e2e41fad88db96,
title = "TGF-β and Hepatocellular Carcinoma: When A Friend Becomes An Enemy",
abstract = "Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy. A key molecular player capable of modulating cell growth and fibrosis is the Transforming Growth Factor-beta (TGF-β). Interestingly, TGF-β seems to act like a switch, since it has dual and opposite roles during early and late phases of cancer development. Therefore to develop therapies that target TGF-β signaling pathway for HCC treatment is important to understand the underlying pathogenetic mechanisms at play with special emphasis in the crosstalk between TGF-β and other signaling pathways. In recent years, a plethora of TGR-β have been developed and some of them are under clinical investigations for testing in patients with advanced HCC. In this review, we summarize recent knowledge about the role of TGF-β signaling pathway in HCC progression.",
keywords = "cirrhosis, HCC, hepatocellular carcinoma, liver cancer, pathogenesis., TGF-β",
author = "Marco Arrese and Alejandra Hernandez and Luis Astete and Lisbell Estrada and Claudio Cabello-Verrugio and Daniel Cabrera",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389203718666171117112619",
language = "English",
volume = "19",
pages = "1172--1179",
journal = "Current Protein and Peptide Science",
issn = "1389-2037",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TGF-β and Hepatocellular Carcinoma : When A Friend Becomes An Enemy. / Arrese, Marco; Hernandez, Alejandra; Astete, Luis; Estrada, Lisbell; Cabello-Verrugio, Claudio; Cabrera, Daniel.

En: Current protein & peptide science, Vol. 19, N.º 12, 01.01.2018, p. 1172-1179.

Resultado de la investigación: Article

TY - JOUR

T1 - TGF-β and Hepatocellular Carcinoma

T2 - When A Friend Becomes An Enemy

AU - Arrese, Marco

AU - Hernandez, Alejandra

AU - Astete, Luis

AU - Estrada, Lisbell

AU - Cabello-Verrugio, Claudio

AU - Cabrera, Daniel

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy. A key molecular player capable of modulating cell growth and fibrosis is the Transforming Growth Factor-beta (TGF-β). Interestingly, TGF-β seems to act like a switch, since it has dual and opposite roles during early and late phases of cancer development. Therefore to develop therapies that target TGF-β signaling pathway for HCC treatment is important to understand the underlying pathogenetic mechanisms at play with special emphasis in the crosstalk between TGF-β and other signaling pathways. In recent years, a plethora of TGR-β have been developed and some of them are under clinical investigations for testing in patients with advanced HCC. In this review, we summarize recent knowledge about the role of TGF-β signaling pathway in HCC progression.

AB - Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide accounting for more than 700 thousand deaths per year. Most of the HCC develops in a cirrhotic liver, a microenvironment where fibrotic tissue replaces parenchymal cells. Thus, there is a close connection between fibrosis and HCC development. Understanding the cellular and molecular mechanisms involved in this process is a crucial step to advance in novel therapeutic or pharmacological strategies to prevent or improve the course of this malignancy. A key molecular player capable of modulating cell growth and fibrosis is the Transforming Growth Factor-beta (TGF-β). Interestingly, TGF-β seems to act like a switch, since it has dual and opposite roles during early and late phases of cancer development. Therefore to develop therapies that target TGF-β signaling pathway for HCC treatment is important to understand the underlying pathogenetic mechanisms at play with special emphasis in the crosstalk between TGF-β and other signaling pathways. In recent years, a plethora of TGR-β have been developed and some of them are under clinical investigations for testing in patients with advanced HCC. In this review, we summarize recent knowledge about the role of TGF-β signaling pathway in HCC progression.

KW - cirrhosis

KW - HCC

KW - hepatocellular carcinoma

KW - liver cancer

KW - pathogenesis.

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=85054774547&partnerID=8YFLogxK

U2 - 10.2174/1389203718666171117112619

DO - 10.2174/1389203718666171117112619

M3 - Article

C2 - 29150921

AN - SCOPUS:85054774547

VL - 19

SP - 1172

EP - 1179

JO - Current Protein and Peptide Science

JF - Current Protein and Peptide Science

SN - 1389-2037

IS - 12

ER -